Retention Rates and Successful Treatment with Antiseizure Medications in Newly-Diagnosed Epilepsy Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Treatment for epilepsy primarily involves antiseizure medications (ASMs), which can be characterized using the clinical data warehouse (CDW) database. In this study, we compared retention rates and time to successful treatment for various ASMs to reflect both efficacy and adverse effects in patients with newly diagnosed epilepsy. Materials and Methods: We identified newly diagnosed epilepsy patients with ASM treatment for more than 12 months using CDW of a tertiary referral hospital. Clinical characteristics were compared between groups with successful and unsuccessful treatment. Cox regression analysis was performed to evaluate independent variables of age, sex, comorbidities, and attributes of ASM regimens. Results: Of 2515 eligible participants, 46.2% were successfully treated with the first ASM regimen, and 74.7% with all ASM regimens with the median time-to-treatment success of 14 months. Participants with second-generation ASM as the first ASM were more like ly to be successfully treated with the first regimen compared to those with first-generation ASM (51.6% vs. 42.3%, p<0.001) and more successfully treated [hazard ratio (HR)=1.26; 95% confidence interval (CI): 1.15–1.39]. Overall, valproic acid was the most common ASM across a wide range of ages under 65 years, while levetiracetam in patients aged over 65 years or lamotrigine in female adult patients. Clinical factors associated with less favorable treatment outcomes included renal disease (HR=0.78; 95% CI: 0.66–0.92), liver disease (HR=0.65; 95% CI: 0.52–0.81), depression (HR=0.70; 95% CI: 0.57–0.84), and mechanical ventilation (HR=0.58; 95% CI: 0.50–0.67). Conclusion: Second-generation ASMs have the advantage of more successful treatment with fewer ASM regimen changes com pared with first-generation drugs. Various comorbid conditions as well as age and sex should be considered when selecting ASMs.
Abstract
Purpose: Treatment for epilepsy primarily involves antiseizure medications (ASMs), which can be characterized using the clinical data warehouse (CDW) database. In this study, we compared retention rates and time to successful treatment for various ASMs to reflect both efficacy and adverse effects in patients with newly diagnosed epilepsy. Materials and Methods: We identified newly diagnosed epilepsy patients with ASM treatment for more than 12 months using CDW of a tertiary referral hospital. Clinical characteristics were compared between groups with successful and unsuccessful treatment. Cox regression analysis was performed to evaluate independent variables of age, sex, comorbidities, and attributes of ASM regimens. Results: Of 2515 eligible participants, 46.2% were successfully treated with the first ASM regimen, and 74.7% with all ASM regimens with the median time-to-treatment success of 14 months. Participants with second-generation ASM as the first ASM were more like ly to be successfully treated with the first regimen compared to those with first-generation ASM (51.6% vs. 42.3%, p<0.001) and more successfully treated [hazard ratio (HR)=1.26; 95% confidence interval (CI): 1.15–1.39]. Overall, valproic acid was the most common ASM across a wide range of ages under 65 years, while levetiracetam in patients aged over 65 years or lamotrigine in female adult patients. Clinical factors associated with less favorable treatment outcomes included renal disease (HR=0.78; 95% CI: 0.66–0.92), liver disease (HR=0.65; 95% CI: 0.52–0.81), depression (HR=0.70; 95% CI: 0.57–0.84), and mechanical ventilation (HR=0.58; 95% CI: 0.50–0.67). Conclusion: Second-generation ASMs have the advantage of more successful treatment with fewer ASM regimen changes com pared with first-generation drugs. Various comorbid conditions as well as age and sex should be considered when selecting ASMs.
참고문헌 (24)
- Fisher RS, "ILAE official report : a practical clinical definition of epilepsy", Epilepsia, 55, pp.475~482 (2014)
- Fiest KM, "Prevalence and incidence of epilepsy : a systematic review and meta-analysis of international studies", Neurology, 88, pp.296~303 (2017)
- Rho JM, "Brief history of anti-seizure drug development", Epilepsia Open, 3(Suppl 2), pp.114~119 (2018)
- French JA, "Rational polytherapy", Epilepsia, 50(Suppl 8), pp.63~68 (2009)
- Brodie MJ, "Antiepileptic drug therapy the story so far", Seizure, 19, pp.650~655 (2010)
- Títoff V, "Seizures, antiepileptic drugs, and CKD", Am J Kidney Dis, 73, pp.90~101 (2019)
- Lacerda G, "Optimizing therapy of seizures in patients with renal or hepatic dysfunction", Neurology, 67(12 Suppl 4), pp.S28~S33 (2006)
- Harden C, "Safety profile of levetiracetam", Epilepsia, 42(Suppl 4), pp.36~39 (2001)
- Ettinger AB, "Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel", Epilepsia, 56, pp.1252~1263 (2015)
- Kanner AM, "Depression and epilepsy : a bidirectional relation?", Epilepsia, 52(Suppl 1), pp.21~27 (2011)
- Honybun E, "Prenatal valproate exposure and adverse neurodevelopmental outcomes : does sex matter?", Epilepsia, 62, pp.709~719 (2021)
- Vajda FJ, "The teratogenic risk of antiepileptic drug polytherapy", Epilepsia, 51, pp.805~810 (2010)
- Hakeem H, "Development and validation of a deep learning model for predicting treatment response in patients with newly diagnosed epilepsy", JAMA Neurol, 79, pp.986~996 (2022)
- Quan H, "Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data", Med Care, 43, pp.1130~1139 (2005)
- Brodie MJ, "Patterns of treatment response in newly diagnosed epilepsy", Neurology, 78, pp.1548~1554 (2012)
- Chen Z, "Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs : a 30-year longitudinal cohort study", JAMA Neurol, 75, pp.279~286 (2018)
- Kwan P, "Refractory epilepsy: a progressive, intractable but preventable condition?", Seizure, 11, pp.77~84 (2002)
- Dash D, "Effect of reduction of antiepileptic drugs in patients with drug-refractory epilepsy", Seizure, 27, pp.25~29 (2015)
- Ficker DM, "Epileptiform abnormalities in hepatic encephalopathy", J Clin Neurophysiol, 14, pp.230~234 (1997)
- Rudler M, "Status epilepticus in patients with cirrhosis : how to avoid misdiagnosis in patients with hepatic encephalopathy", Seizure, 45, pp.192~197 (2017)
- Kobau R, "Prevalence of self-reported epilepsy or seizure disorder and its associations with self-reported depression and anxiety : results from the 2004 healthstyles survey", Epilepsia, 47, pp.1915~1921 (2006)
- Strine TW, "Psychological distress, comorbidities, and health behaviors among U. S. adults with seizures : results from the 2002 national health interview survey", Epilepsia, 46, pp.1133~1139 (2005)
- Josephson CB, "Association of depression and treated depression with epilepsy and seizure outcomes : a multicohort analysis", JAMA Neurol, 74, pp.533~539 (2017)
- Devinsky O, "Changing the approach to treatment choice in epilepsy using big data", Epilepsy Behav, 56, pp.32~37 (2016)